Involving Luciferase Patents (Class 435/8)
  • Patent number: 11034886
    Abstract: Novel compounds in the classes of Imidazo[1,2-?]pyrazines and Imidazo[1,2-?]quinoxalines with a methoxy group modification show unique spectral properties when used as a substrate for luciferases and photo-proteins. Methoxy e-Coelenterazine, an Imidazo[1,2-?] quinoxaline shifts the emission wavelength by 80 nm to blue light compared to e-Coelenterazine, using Renilla reniformis luciferase. The novel analogues described here are useful in combination with fluorescent proteins to create BRET (bioluminescent resonance energy transfer) and for other luminescent assays. In addition these novel compounds can be used to enhance, dazzle, amaze, startle, and otherwise entertain an audience by their direct application on to the audience, surroundings, the actors, or sprayed on settings as in the newer 4D movies.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: June 15, 2021
    Assignee: Prolume, LTD.
    Inventors: Bruce Bryan, Hendrik Schmidt, Millard Cull
  • Patent number: 10962512
    Abstract: A pathogen surrogate, formed by a DNA tag or bar code and a carrier, is described for use in the validation and verification of sanitation, such as in food processing operations and for wash water systems for fresh produce. The carrier material is selected so that the pathogen surrogate mimics the behavior of a pathogen when subjected to a sanitation operation. One or more surrogates can be introduced in to an environment, which is then subjected to sanitation process, followed by a detection process using the DNA tag of the surrogate.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: March 30, 2021
    Assignee: Safetraces, Inc.
    Inventors: Antonios Zografos, George Roy Farquar, John Mark Carter
  • Patent number: 10648026
    Abstract: This invention provides nucleoside polyphosphate analogs each of which comprises a tag comprising a plurality of Raman-scattering moieties; compounds comprising said nucleoside polyphosphate analogs; and methods for determining the sequence of a single-stranded DNA or RNA using said nucleoside polyphosphate analogs. This invention also provides methods for detecting the interaction of a plurality of predetermined compounds, at least one of which having attached thereto a tag comprising a plurality of Raman-scattering moieties.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 12, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Jingyue Ju, Shiv Kumar, Mirkó Palla, James J. Russo
  • Patent number: 10556032
    Abstract: A sanitation management system maintains records of exemplary locations on an item to be sanitized and indicates those locations to a person or system charged with applying a pathogen surrogate prior to a sanitation process. The sanitation management system maintains records of where the pathogen surrogate was applied prior to the sanitation process. Following the sanitation process, the sanitation management system indicates to an inspector, or an inspection system, locations of where the pathogen surrogate was applied for the purpose of facilitating testing of the sanitation process by checking for the presence of the pathogen surrogate at some or all of those locations. This can ensure that the inspection process is relevant to the sanitation process and less likely to generate false negatives where the inspection finds a lack of the pathogen surrogate not due to cleaning, but due to lack of application of the pathogen surrogate.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: February 11, 2020
    Assignee: SafeTraces, Inc.
    Inventors: Antonios Zografos, Laurie M. Clotilde, Peter Mattei
  • Patent number: 10308975
    Abstract: Described are substituted imidazo[1,2-a]pyrazine compounds, which are coelenterazine analogs, kits comprising the compounds, and methods of using the compounds for the detection of luminescence in luciferase-based assays. Also described are methods for making the compounds, such as a method using aminopyrazine acetophosphonates as synthesis intermediates.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: June 4, 2019
    Assignee: Promega Corporation
    Inventors: Anton Shakhmin, Thomas Kirkland, Joel Walker, Thomas Machleidt, Mary Hall, Keith V. Wood
  • Patent number: 10214766
    Abstract: The invention relates to a bioluminescent substrate suitably usable in a series of artificial luciferases (ALuc), and the invention provides a wavelength-shifted spectrum with a selective high intensity luminescence and high luminescence stability obtained by the use of the substrate together with ALuc. The luminescent substrate for ALuc obtained by the invention can be included together with a suitable luminescence solution in a luminescence kit. The bioluminescent substrate for ALuc of the invention can exhibit unprecedented excellent luminescence specificity and functionality in the conventional bioluminescence probe, two-hybrid assay, bioluminescent capsule, and reporter gene assay.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: February 26, 2019
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Sung Bae Kim, Hiroshi Izumi, Hiroaki Tao, Masaki Torimura, Akihiro Wakisaka
  • Patent number: 10131931
    Abstract: A method for determining whether bacteria in a sample obtained from a subject at a point of care in a clinical setting is susceptible to an antibiotic, within a time period associated with a point of care. The method includes measuring a bioluminescent indication from a first test sample based on released ATP to determine a characteristic associated with the bioluminescent indication and comparing the characteristic associated with the bioluminescent indication to a first threshold. The method includes determining whether a bacteria is present by comparing the difference between a characteristic associated with a first confirmatory bioluminescent signal and a characteristic associated with a second confirmatory bioluminescent signal to an confirmatory threshold.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: November 20, 2018
    Assignee: RONALD TURNER
    Inventor: Ronald Turner
  • Patent number: 10067149
    Abstract: The present invention provides compositions and methods for detection and analysis of intracellular binding of a bioactive agent to a cellular target. In particular, provided herein are bioactive agents tethered to fluorophores, cellular targets fused to bioluminescent reporters, and methods of detecting and analyzing the interaction of bioactive agents with cellular targets therewith.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 4, 2018
    Assignee: Promega Corporation
    Inventors: Carolyn W. Hitko, Thomas Kirkland, Thomas Machleidt, Rachel Friedman Ohana, Matt Robers, Keith Wood
  • Patent number: 10024862
    Abstract: The present invention provides compositions and methods for detection and analysis of intracellular binding of a bioactive agent to a cellular target. In particular, provided herein are bioactive agents tethered to fluorophores, cellular targets fused to bioluminescent reporters, or portions, components, or subunits of bioluminescent reporters, and methods of detecting and analyzing the interaction of bioactive agents with cellular targets therewith.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: July 17, 2018
    Assignee: Promega Corporation
    Inventors: Carolyn W. Hitko, Thomas Kirkland, Thomas Machleidt, Rachel Friedman Ohana, Matt Robers, Keith Wood
  • Patent number: 9988663
    Abstract: Provided is a device for collecting biological material from a microbe, the device including: a collection container that is used to collect a microbe from a liquid sample containing the microbe and to extract the biological material from the microbe; and a temperature control mechanism that controls a temperature of the collection container. Herein, the temperature control mechanism controls a temperature of the collection container so that the microbe is collected at a first temperature and the biological material is extracted from the microbe at a second temperature higher than the first temperature.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: June 5, 2018
    Assignee: HITACHI, LTD.
    Inventors: Noe Miyashita, Shuichi Mori, Yuta Nakatsuka
  • Patent number: 9924073
    Abstract: Described are substituted imidazo[1,2-a]pyrazine compounds, which are coelenterazine analogs, kits comprising the compounds, and methods of using the compounds for the detection of luminescence in luciferase-based assays. Also described are methods for making the compounds, such as a method using aminopyrazine acetophosphonates as synthesis intermediates.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: March 20, 2018
    Assignee: PROMEGA CORPORATION
    Inventors: Anton Shakhmin, Thomas Kirkland, Joel Walker, Thomas Machleidt, Mary Hall, Keith V. Wood
  • Patent number: 9676997
    Abstract: Disclosed herein are compositions and methods for stabilizing a luminogenic substrate such as coelenterazine or a functional analog thereof. The functional analog may be furimazine. The composition may include the luminogenic substrate, a thionucleoside, and an organic solvent, in which the thionucleoside is present in an amount effective to stabilize the luminogenic composition against decomposition. The method provided herein stabilizes the luminogenic substrate against decomposition by contacting the luminogenic substrate with an effective amount of the thionucleoside in the presence of the organic solvent. Also provided herein is a kit containing the composition.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: June 13, 2017
    Assignee: PROMEGA CORPORATION
    Inventors: Thomas Kirkland, Keith V. Wood, Mary Hall, Marie Schwinn
  • Patent number: 9499809
    Abstract: The invention relates to a chimeric protein comprising or consisting of, from N-terminal to C-terminal, (a) a N-terminal part of a Bordetella CyaA protein (b) a heterologous polypeptide, and (c) a C-terminal part of a Bordetella CyaA protein. The invention also relates to a polynucleotide encoding a deleted version of a Bordetella CyaA, as well as a polynucleotide encoding this chimeric protein. A composition comprising at least one chimeric protein(s) of the invention and the prophylactic and/or therapeutic uses of said composition are also part of the invention.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: November 22, 2016
    Assignee: GENTICEL
    Inventors: Yolande Misseri, Michael Esquerre, Etienne Joly
  • Patent number: 9447450
    Abstract: Novel red-shifted luciferin derivatives and uses of those compounds are provided.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: September 20, 2016
    Assignee: PROMEGA CORPORATION
    Inventor: Carolyn Woodroofe Hitko
  • Patent number: 9422591
    Abstract: Methods and kits for determining if one or more animals have mastitis and for monitoring animals and the quality of the milk they produce are disclosed. Kits and test assays disclosed are used to determine the quantity of proteasomes and proteins thereof, the activity of proteasome enzymes, the quantity of proteasome bound and regulating proteins, and the quantity of ubiquinated protein. Components and reagents for use in the kits and assays are also disclosed.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: August 23, 2016
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventor: Kiran Madura
  • Patent number: 9328326
    Abstract: The present invention relates to a method for isolating cells from a complex sample comprising the steps of: a) providing a complex sample, b) incubating said sample with: at least one chaotrope, a buffer and at least one detergent, c) isolating said cells from the resulting mixture by centrifugation or filtration.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: May 3, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Peter Rossmanith, Ingeborg Hein, Martin Wagner
  • Patent number: 9273343
    Abstract: The present invention provides compounds and methods for assaying redox state of metabolically active cells and methods for assaying enzyme activity and/or metabolite level by coupling to redox defining co-factor NAD(P)/NAD(P)H measurement.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: March 1, 2016
    Assignee: PROMEGA CORPORATION
    Inventors: James J. Cali, Sarah Duellman, Dieter Klaubert, Donna Leippe, Martha O'Brien, John Shultz, Jolanta Vidugiriene, Wenhui Zhou, Mary Sobol
  • Patent number: 9234186
    Abstract: The present invention relates to a luciferase derived from a star-worm belonging to genus Diplocladon, the luciferase inducing luminescence such that a maximum luminous wavelength falls within a range of 557 to 562 nm over the entire pH range of 5.5 to 8.0, or the luciferase inducing luminescence having 1.5 times the luminous intensity of luminescence induced by Photinus pyralis firefly luciferase.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: January 12, 2016
    Assignees: OLYMPUS CORPORATION, NIMURA GENETIC SOLUTIONS CO., LTD., PERAK STATE DEVELOPMENT CORPORATION
    Inventors: Ryutaro Akiyoshi, Katsunori Ogo, Hirobumi Suzuki
  • Patent number: 9138439
    Abstract: The present invention relates to a method for identifying compounds that modulate the activity of p300/CBP. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the newly identified lysine-CoA inhibitor binding site, L1 loop, electronegative pocket, or electronegative groove of the HAT domain of p300/CBP and testing the compound for its ability to modulate the activity of p300/CBP. Compositions and methods for preventing or treating diseases or disorders associated with p300/CBP are also provided as is a method for producing a semi-synthetic HAT domain.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: September 22, 2015
    Assignees: The Wistar Institute, The Johns Hopkins University
    Inventors: Ronen Marmorstein, Xin Liu, Philip A. Cole, Ling Wang, Erin M. Bowers, David J. Meyers, Chandrani Mukherjee
  • Patent number: 9107953
    Abstract: An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: August 18, 2015
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventor: Yasuhiko Tabata
  • Patent number: 9046523
    Abstract: An assay is provided for detecting the activity of a reporter kinase comprising (i) adding said reporter kinase to an assay mixture wherein said reporter kinase is contacted with bioluminescent reagent no more than 5 minutes after being contacted with ADP, and wherein, prior to contacting the reporter kinase with ADP, the assay mixture is substantially free from kinase other than reporter kinase; and (ii) detecting light output from the assay mixture. Methods for detecting the presence of an analyte in a sample and methods for validating a treatment process using the above assay are also provided. Further provided are devices for conducting these assays and methods.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: June 2, 2015
    Assignee: THE SECRETARY OF STATE FOR HEALTH
    Inventors: Mark J. Sutton, Toryn Poolman, Richard J. Hesp
  • Publication number: 20150148256
    Abstract: A bioluminescence imaging-based high-throughput assay for inhibitors of ABCG2 is described. Compositions of inhibitors of ABCG2 and methods of using ABCG2 inhibitors are also described.
    Type: Application
    Filed: August 21, 2014
    Publication date: May 28, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN GILBERT POMPER, YIMAO ZHANG, JOHN LATERRA
  • Publication number: 20150140583
    Abstract: A rapid, sensitive method of separating and detecting microorganisms from a sample containing microorganisms, such as but not limited to bacteria, fungi, yeast, viruses, and the like. The method relies on separation techniques to separate and concentrate the cells from the sample, together with chemical techniques to amplify the amount of detectable signal from low numbers of cells to provide a rapid and sensitive method of detecting microorganisms. This detection method may utilize: a filtration device; a centrifugation device; a system; a swab device; and kit comprising one or more of the devices and components to perform the present method of separating and detecting microorganisms in a sample containing microorganisms. The sample may be a chemical, cosmetic, personal care, pharmaceutical, or consumable good in its raw material, in-process, and/or finished product states that needs to be tested for any contaminating microorganisms prior to shipment to the consumer.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 21, 2015
    Applicant: Celsis International Limited
    Inventors: Andrew Hearn, Lori Daane
  • Patent number: 9029097
    Abstract: The present invention relates to novel biosensors that are based on bioluminescence resonance energy transfer (BRET). These biosensors may be used to monitor rapid interaction and conformational changes within G protein-coupled receptor/G protein complexes and, in this way, reflect the activation status of the receptor. Advantageously, the biosensors may be used as a highly sensitive and quantitative assay for the identification of ligands (agonists, antagonists, inverse agonists, partial agonists, etc.) targeting G protein-coupled receptors (GPCRs) as well as for the analysis of the activation status of these receptors. Moreover, multiplexing different biosensors within receptors/G protein complexes allows for mapping ligand textures. Additionally, the biosensors permit the direct, real-time examination of interactions between receptors and G protein in their natural environment, the living cell.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: May 12, 2015
    Assignee: Universite de Montreal
    Inventors: Michel Bouvier, Céline Gales, Billy Breton
  • Publication number: 20150126438
    Abstract: The invention provides diagnostic and prognostic methods and methods of evaluating treatment protocols for disorders such as obesity, diabetes, metabolic syndrome, cancer and vascular disease by detecting the levels of a novel isoform of ChREBP, termed ChREBP ?. The invention also provides nucleic acids, proteins, reporter constructs based on ChREBP ? and methods of identifying one or more agents that modulate the expression of a ChREBP ? target gene.
    Type: Application
    Filed: January 22, 2013
    Publication date: May 7, 2015
    Inventors: Mark A. Herman, Barbara B. Kahn
  • Publication number: 20150111229
    Abstract: It is intended to identify a substance inhibiting an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone. The present invention provides a method for searching for an inhibitor of an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone, comprising: adding a test substance and 2,5-dimethyl-4-hydroxy-3(2H)-furanone to an olfactory receptor OR5K1 or a polypeptide having at least 80% amino acid sequence identity thereto; measuring the response of the olfactory receptor or the polypeptide to 2,5-dimethyl-4-hydroxy-3(2H)-furanone; and identifying a test substance inhibiting the response of the olfactory receptor or the polypeptide, on the basis of the measured response.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 23, 2015
    Applicant: Kao Corporation
    Inventors: Aya NAMBA, Naoko Saito, Michiaki Inoue, Tsuyoshi Toyabe
  • Publication number: 20150111233
    Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Satoshi INOUYE, Junichi SATO
  • Patent number: 9012164
    Abstract: Disclosed herein are methods for determining the amount or activity of one or more luciferases and methods for measuring the luminescent signal generated by one or more luciferases in a sample, the methods comprising incubating the sample with a reactive substrate(s) of the luciferase(s) to be analyzed and a reducing agent to inactivate a first luciferase, wherein the first luciferase, in its native form, is a secreted luciferase.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 21, 2015
    Inventors: Marco Peter Leu, John Michael Daly
  • Publication number: 20150104787
    Abstract: Methods and systems are provided for packaging reporter nucleic acid molecules into non-replicative transduction particles for use as reporter molecules. The non-replicative transduction particles can be constructed from viruses and use viral transduction and replication systems. The reporter nucleic acid molecules include a reporter gene, such as a reporter molecule or selectable marker, for detecting target genes or cells. Methods and systems are provided for detection of cells and target nucleic acid molecules using the non-replicative transduction particles as reporter molecules.
    Type: Application
    Filed: November 21, 2014
    Publication date: April 16, 2015
    Inventors: Diego Ariel Rey, Nikol DeForest, Heather Cox, Soni Shukla
  • Patent number: 8999896
    Abstract: Screening assays that allow for the identification of agents that modulate the activity of N-terminal acetylation of a polypeptide and the Doa10 branch of the N-end rule pathway are provided. Also provided are methods of using an agent that modulates the activity of N-terminal acetylation of a polypeptide and the Doa10 branch of the N-end rule pathway to increase or decrease protein degradation in a cell, and to modulate physiologic and pathologic associated with N-terminal acetylation of a polypeptide and the Doa10 branch of the N-end rule pathway.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: April 7, 2015
    Assignee: California Institute of Technology
    Inventors: Cheol-Sang Hwang, Anna Shemorry, Alexander Varshavsky
  • Patent number: 8986940
    Abstract: Provided is a method of detecting infection in a wound caused by an infecting organism at a wound site. Also provided is a system for detecting an infection in a wound at a wound site. Additionally, a porous pad comprising luciferase is provided.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: March 24, 2015
    Assignee: KCI Licensing, Inc.
    Inventors: Amy K. McNulty, Deepak V. Kilpadi, George Hutchinson, Nancy Price
  • Publication number: 20150080256
    Abstract: A luminescence detecting apparatus and method for analyzing luminescent samples is disclosed. Luminescent samples are placed in a plurality of sample wells in a tray, and the tray is placed in a visible-light impervious chamber containing a charge coupled device camera. The samples may be injected in the wells, and the samples may be injected with buffers and reagents, by an injector. In the chamber, light from the luminescent samples pass through a collimator, a Fresnel field lens, a filter, and a camera lens, whereupon a focused image is created by the optics on the charge-coupled device (CCD) camera. The use of a Fresnel field lens, in combination with a collimator and filter, reduces crosstalk between samples below the level attainable by the prior art. Preferred embodiments of the luminescence detecting apparatus and method disclosed include central processing control of all operations, multiple wavelength filter wheel, and robot handling of samples and reagents.
    Type: Application
    Filed: October 15, 2014
    Publication date: March 19, 2015
    Inventors: Michael R. GAMBINI, Jeff A. Levi, John C. Voyta, John G. Atwood, Bruce E. DeSimas, II, Edward J. Lakatos, Israel Metal, George Sabak, Yongdong Wang
  • Publication number: 20150071859
    Abstract: The present disclosure encompasses embodiments of nucleic acid minicircle vectors most advantageous for the detection of tumor cells. In particular, the minicircles of the disclosure incorporate a tumor-specific promoter operably linked to a nucleotide sequence desired to be selectively expressed in a tumor cell or a tissue comprising a population of tumor cells. In embodiments of the disclosure, the minicircle vectors comprise a tumor-specific promoter operably linked to a nucleotide sequence encoding a polypeptide useful as a reporter. Accordingly, when expressed by a recipient tumor cell, the reporter may be detectable, thereby providing information such as a visual image of the tumor cell and/or its location in a tissue of the subject human or non-human animal.
    Type: Application
    Filed: September 9, 2014
    Publication date: March 12, 2015
    Inventors: Sanjiv S. Gambhir, John A. Ronald
  • Patent number: 8975293
    Abstract: This disclosure describes methods of screening for compounds that disrupt the interaction between DNMT1 and the gamma-globin promoter or between LSD-1 and the gamma-globin promoter. This disclosure describes methods of screening for compounds that de-repress the gamma-globin gene.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: March 10, 2015
    Assignee: Regents of the University of Michigan
    Inventors: James Douglas Engel, Osamu Tanabe, Lihong Shi
  • Publication number: 20150064731
    Abstract: The present invention provides, among other things, imidazo[1,2-?]pyrazine derivatives according for Formula (Ia) or Formula (Ib). The derivatives are useful in any method which other coelenterazines have been used. For example, the derivatives may be used in a bioluminogenic method to detect the presence of certain compounds or molecules.
    Type: Application
    Filed: August 18, 2014
    Publication date: March 5, 2015
    Inventors: Dieter H. Klaubert, Poncho Meisenheimer, James Unch
  • Publication number: 20150056631
    Abstract: The present invention relates to methods and compositions for diagnosing a disease or disorder in a subject by introducing into cells of the subject a diagnostic gene switch construct and monitoring expression of a reporter gene. The invention further relates to methods and compositions for monitoring the progression of a disease or disorder or the effectiveness of a treatment for a disease or disorder.
    Type: Application
    Filed: August 14, 2014
    Publication date: February 26, 2015
    Inventors: Robert P. BEECH, Thomas D. Reed, Robert Patzig
  • Publication number: 20150044709
    Abstract: The present invention is concerned with test systems for determining the activity of neurotoxin polypeptides. Specifically, it relates to a polynucleotide encoding a single chain luciferase fusion polypeptide comprising: (i) a LuxB subunit, (ii) a linker comprising a neurotoxin cleavage site, and (iii) a LuxA subunit and a polypeptide encoded by the polynucleotide. Further provided in accordance with the invention are a vector and a host cell comprising the polynucleotide. Moreover, the present invention relates to a method for determining a proteolytically active neurotoxin polypeptide in a sample and a kit for carrying out the method.
    Type: Application
    Filed: March 7, 2013
    Publication date: February 12, 2015
    Inventor: Karl-Heinz Eisele
  • Publication number: 20150044710
    Abstract: Disclosed herein are methods, compositions and devices for detecting oxygen in various samples such as environmental and biological samples.
    Type: Application
    Filed: August 8, 2014
    Publication date: February 12, 2015
    Inventors: Anjan Kr. DASGUPTA, Sanhita RAY, Arumoy CHATTERJEE, Tamoghna BHATTACHARYYA, Satarupa BHADURI, Anirban BOSE
  • Patent number: 8951745
    Abstract: The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4 (=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: February 10, 2015
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Christof Niehrs, Wei Wu, Andrey Glinka, Olga Kazanskaya
  • Patent number: 8945862
    Abstract: Embodiments of the present disclosure include triple-fusion human embryonic stem cells, methods of imaging triple-fusion human embryonic stem cells, triple-fusion polynucleotides, triple-fusion proteins, methods of monitoring the progression of human embryonic stem cells, methods of making isolated triple-fusion human embryonic stem cells, and the like.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: February 3, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Joseph Ching-Ming Wu, Feng Cao, Sanjiv Sam Gambhir
  • Publication number: 20150025044
    Abstract: A screening method for identifying compounds that alter the fidelity with which the initiation codon in mRNAs is recognized by the translational apparatus in eukaryotes is disclosed. This screening method was used to identify compounds having such activity. Methods of altering the fidelity of initiation codon selection are also disclosed. Methods of treating disorders characterized by single nucleotide mutations in initiation codons using compounds identified by the screening method, as well as methods of treating fungal and parasitic infections and hyperproliferative disorders using compounds identified by the screening method are also disclosed.
    Type: Application
    Filed: June 30, 2014
    Publication date: January 22, 2015
    Inventors: Jon R. Lorsch, Julie Ellen Takacs, Timothy Brian Neary
  • Patent number: 8937183
    Abstract: The present invention provides compounds useful for detection of hydrogen peroxide and methods of using same.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: January 20, 2015
    Assignee: Promega Corporation
    Inventors: Dieter Klaubert, John Shultz, James Unch, Michael P. Valley, Hui Wang, Wenhui Zhou
  • Publication number: 20150017663
    Abstract: Provided herein are methods of evaluating potential antitumor compounds, and thereby identifying antitumor compounds, using placenta or a portion thereof and tumor cells, and compositions for accomplishing the same. In one embodiment, provided herein is a method of determining whether a potential antitumor compound is effective against a plurality of tumor cells, comprising introducing a plurality of tumor cells to, e.g., into or onto, a mammalian placenta or portion thereof; contacting said plurality of tumor cells for a period of time with said antitumor compound; and determining whether said antitumor compound is effective against said tumor cells, wherein said antitumor compound is effective against said tumor cells if said antitumor compound over said period of time reduces the number of said tumor cells or reduces the growth rate of said tumor cells.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 15, 2015
    Applicant: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohit B. Bhatia, Qian Ye
  • Patent number: 8932818
    Abstract: The present invention relates to compounds that modulate ribosomal frameshifting and nucleic acid constructs for use in methods for identifying or validation of compounds that modulate ribosomal frameshifting. In particular, the present invention relates to the use of nucleic acid constructs to identify or validate compounds capable of modulating the efficiency of programmed ribosomal frameshifting and the use of compounds that modulate the efficiency of programmed ribosomal frameshifting to inhibit the replication or infectivity of viruses that employ programmed ribosomal frameshifting.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: January 13, 2015
    Assignee: PTC Therapeutics, Inc.
    Inventors: Sergey V. Paushkin, Nikolai A. Naryshkin, Ellen Welch
  • Publication number: 20150010932
    Abstract: Provided herein is an assay for interrogating transient and dynamic protein-protein interactions and for screening and characterizing agents as agonists or antagonists of protein-protein interactions. The methods can provide a single assay for simultaneously assessing the bioavailability and efficacy of a test compound for increasing or decreasing a protein-protein interaction of interest.
    Type: Application
    Filed: July 1, 2014
    Publication date: January 8, 2015
    Inventors: Geoffrey Wahl, Yao-Cheng Li
  • Publication number: 20150010933
    Abstract: The present invention includes a luciferase-based high-throughput screening assay that identifies compounds that are inhibitors of cellular metabolism. This assay is applicable to all bacterial and eukaryotic membranes.
    Type: Application
    Filed: February 13, 2013
    Publication date: January 8, 2015
    Inventors: Harvey Rubin, Takahiro Yano
  • Publication number: 20150010931
    Abstract: A cell based assay for detection for protease activity is disclosed. In the assay a cell is engineered to express a protease substrate with at least one label, preferably on its C-terminus. Cleavage of the substrate by the protease that recognizes it results in a C-terminal fragment and a N-terminal fragment, where the fragment having the label is subject to ubiquitin proteasome degradation. The assay measures the disappearance of the label due to degradation of the fragment to which it is attached. A cell free assay is also described for detection of protease activity. In the cell free assay, the protease substrate is expressed in a solution that includes the elements of the ubiquitin proteasome pathway for degradation of the fragment. The assay measures the disappearance of the label attached to the fragment that results from cleavage by the protease.
    Type: Application
    Filed: June 13, 2011
    Publication date: January 8, 2015
    Applicant: Synaptic Research, LLC
    Inventors: George A. Oyler, Yien Che Tsai
  • Patent number: 8921056
    Abstract: The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: December 30, 2014
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Christof Niehrs, Wei Wu, Andrey Glinka, Olga Kazanskaya
  • Publication number: 20140378536
    Abstract: Parkinson's disease is caused by the preferential loss of substantia nigra dopamine neurons. A Parkin Interacting Substrate, PARIS (ZNF746) is identified. The levels of PARIS are regulated by the ubiquitin proteasome system via binding to and ubiquitination by the E3 ubiquitin ligase, parkin. PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human brain Parkinson's disease patients. PARIS represses the expression of the transcriptional co-activator, PGC-1? and the PGC-1? target gene, NRF-1 by binding to insulin response sequences in the PGC-1? promoter. Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons that is PARIS dependent. Overexpression of PARIS causes selective loss of DA neurons in the substantia nigra, which is reversed by either parkin or PGC-1? co-expression. The identification of PARIS provides a molecular mechanism for neurodegeneration due to parkin inactivation.
    Type: Application
    Filed: September 12, 2014
    Publication date: December 25, 2014
    Applicant: VALTED, LLC
    Inventors: Ted M. Dawson, Valina L. Dawson, Han Seok Ko, Jooho Shin
  • Publication number: 20140380514
    Abstract: The invention provides compounds, compositions, methods, substrates, and kits useful for analyzing the metabolic activity in cells, tissue, and animals and for screening test compounds for their effect on cytochrome P450 activity. In particular, a one-step and two-step methods using luminogenic molecules, e.g. luciferins or coelenterazines, that are cytochrome P450 substrates and that are also bioluminescent enzyme, e.g., luciferase, pro-substrates are provided. The present method further provides a method for stabilizing and prolonging the luminescent signal in a luciferase-based assay using luciferase stabilizing agents such as reversible luciferase inhibitors.
    Type: Application
    Filed: June 30, 2014
    Publication date: December 25, 2014
    Inventors: James J. Cali, Dieter Klaubert, William Daily, Samuel Kin Sang Ho, Susan Frackman, Erika Hawkins, Keith V. Wood